[Early Bird Countdown 1 Day] BioCon-Antibody's blockbuster debut agenda is open, from source to CMC to clinical transformation, accelerating FIC drug development

The 9th International Biopharmaceutical Conference Series-Antibody Forum was specially invited Dr.
Dimiter S.
Dimitrov, Director of the Antibody Center, University of Pittsburgh School of Medicine, and former Director of NIH, National Institutes of Health Cancer Center, Dr.
Christian Klein, Director of Roche Swiss R&D Center, Ambrx Dr.
Zhang Shaohui, Senior Vice President of R&D Operations and Head of China Region, Dr.
Zeng Junwei, Vice President of Discovery Biology, Promis Biotechnology, Dr.
Tan Miao, Vice President of Macromolecules R&D of Colombo, Adjunct Professor of Tulane University School of Medicine/Telcon Dr.
Sun Lichun, founder and CEO of Biotech, and other authoritative speakers focused on the early R&D of single/dual/multi-antibody/ADC/X-DC, Biology, innovation and transformation of new targets, druggability, CMC strategy, process development, etc.
Share and communicate
.

Starter Agenda

Innovative Drug Conjugates Session - "Three Elements and Five Elements" of Differentiation Project of R&D and CMC Development of ADCs/XDCs

■ Selection strategy of targets and indications

• Antibody Parts and Conjugation Methods

Research on the properties of better antibodies in ADC drugsNew!
Tan Miao, VP of Macromolecular R&D, Colombo

Stability and effectiveness of ADCs designed by site-specific coupling optimization using unnatural amino acid technologyNew!
Zhang Shaohui, Senior Vice President of R&D Operations, Ambrx, Head of China (Online)

Roundtable discussion: How to break through and innovate the "three components" in the development of differentiated drug conjugates?
Qin Gang, Chairman/President of Qide Pharmaceutical Technology (Suzhou) Co.
, Ltd.

• Linker and Payload

Design and Development Ideas of the ADC Technology Platform in the Post-DS-8201
Era

Research and development of new generation ADC hydrophilic Linker based on in vivo activity, bystander effect and safetyNew!
Liu Haidong, Senior Director of Pufang Biopharmaceuticals Department

Unique "dual control" design: PBD protoxin load and linker ADC development ideas and latest dataNew!
Yu Haixiang, Senior Director of Antibody Research at CStone

Structural Characteristics and Future Prospects of the Fourth Generation Antibody-Drug Conjugates
Cai Jiaqiang, CSO of Suzhou Yilian Biotechnology

■ CMC strategy and development of complex structure from 1 to N

• Development and compliance of CMC process and quality

Compliance Requirements Guidance and Systematic Management Strategies for the "Three Components" of Conjugated Drugs (Proposed)
Shanghai Center for Drug Evaluation and Verification

ADC Drug Process Development and Process Scale-Up Challenges and Solutions

Application of PAT New Technology in Freeze-Drying Process Development and Production
Liu Xiangyun, Product Manager of Texiang Technology

CMC Problems and Exploration of Conjugated Parts in Conjugated DrugsNew!
Yang Jinwei, Director of Zhejiang Xinma Biochemistry

Parameter analysis and CMC strategy in ADC drug development (planned
)

• Other conjugated drug development

Innovative development of new generation ADC drugs such as payload immunotoxinsNew!
Zhu Jianwei, "Zhiyuan" Chair Professor of Shanghai Jiao Tong University, Director of the Antibody Engineering Center of the Ministry of Education

Design and development of PDC-polypeptide conjugated drugsNew!
Sun Lichun, Adjunct Professor at Tulane University School of Medicine, Founder and CEO of Telcon Bio

A case of dual-antibody ADC development based on tumor R&D strategy and mechanism researchNew!
Zhao Yonghao, R&D Director of Jiangsu Corning & Jereh
.
.
.

Innovative Antibody Drugs Session - Early R&D and Druggability/Developability of Targeted, Bi/Multispecific/Functional Antibody Drugs

• Bispecific/functional antibodies

Activating Antibody Discovery/Engineering Platform Construction and Innovative Bispecific Antibody Development
Jieyi Wang, Founder and CEO of Lijin Bio

Qi Bangruo
, Research and Development Director of Shanghai Baiying Biotechnology Co.
, Ltd.

Anti-PD-L1/TIGIT Bispecific Antibody Innovative Development Design and Efficacy OptimizationNew!
Zhu Xiangyang, CEO of Hua Aotai Biotechnology

Next-generation T cell-directed bispecific antibody development and cytokine storm and improved safety researchNew!
Christian Klein, Head of Roche Swiss R&D Center (online)

Key considerations and case sharing for the establishment of immunogenicity methods for new biological drugs
Zhu Yongqin, Senior Technical Director of Xining Biotechnology

Roundtable discussion: How to optimize the structure and molecular design of different double antibodies: stability/purity, higher efficacy, lower toxicity? Wang Jieyi, Founder and CEO
of Lijin Biotechnology Zhu Xiangyang, CEO of Hua Aotai Biotechnology

• Multispecific/Functional Antibodies

Design and Development of Antibody Drugs and Innovative Tertiary Antibodies Targeting EGFR/c-METNew! 
Han Shuhua, Chief Scientific Officer of Jiahe Biotechnology

Immunology and multi-antibody GNC drug development for tumor "targeted immune" therapy
Zhu Yi, Chairman & CSO of Bailey Pharmaceuticals

Fusion of IL-15/IL-15R and double antibody to construct innovative triple antibody molecule and development design (planned)
Qu Xiangdong, founder and general manager of Qiyu Biotechnology

Pathways that reject "involution"/target discovery and combinatorial strategies/biology/mechanisms and early development

• Differentiated target/pathway research/indication development

The latest humanized VH antibody fragment research and the application of new generation double antibody development in anti-tumor and virus New!
Dimiter S.
Dimitrov Director, Antibody Center, University of Pittsburgh School of Medicine, and former Director, NIH, National Institutes of Health Cancer Center (Online)

Innovative non-tumor dual antibody development ideas and target/mechanism differentiation research (proposed) New! 
Jianmin Fang, Co-founder, CEO and Chief Scientific Officer of Rongchang Biotechnology

The world's first target and mechanism research and anti-tumor antibody drug developmentNew! 
Liang Ruian, Founder, Chairman and Chief Executive Officer of China Antibody

Novel cancer immunotherapy Treg-Teff modulators - TNFR2 antibody agonists and antagonistsNew! 
Yin Liusong, Executive President and Chief Scientific Officer of Shenghe (China) Biopharmaceutical Co.
, Ltd.

Pan Liqiang, a new biotech drug targeting tumor
neoantigens, Principal Researcher at the School of Pharmacy, Zhejiang University / Adjunct Professor at the First Hospital of Zhejiang University

• Target combination strategy exploration and validation

Tumor Microenvironment Mechanism Study and Translational Medicine of PD-L1×TGF-βRII Dual Antibody 
Liao Cheng, Deputy General Manager of Hengrui Medicine

Bispecific Antibody Development Based on Anti-4-1BB Nanobody New! 
Andy Tsun Zeng Junwei, Vice President of Discovery Biology, Purmis Biotech

CD47/SIRPα dual antibody target combination selection strategy and clinical research progress
Tian Wenzhi, founder, chairman and general manager of Immune Onco

Tumor Immune Mechanism Study and Biological Considerations of Claudin 18.
2/4-1BB Double Antibody

Research on the Mechanism and Mechanism of Innovative Double Antibody Development and Target Combination
Chen Mingjiu, CEO of Biosyn

Roundtable Discussion: How to innovate dual/polydrug resistant drugs?
• Target selection/combinatorial logic
• Indication selection
• Biology challenge: MOA research
Xie Yizhao, CStone CSO
 …

The BPC 2022 series of innovative drug conferences will be unveiled at Shanghai Marriott Hotel Baohua on March 22-23, 2022
.
The conference is divided into 5 special sessions, ranging from innovative antibody drugs (new targets/mechanisms/Biology/molecular design/ADC and other conjugated drugs/single/double polyclonal antibodies/…), small molecule innovative drugs (PROTAC/AI/CMC change/ Starting from the three dimensions of IND and NDA application), clinical translation and development (clinical value, scientific development), more than 200 leading companies in innovative drug research and development, scientific research scholars, regulatory experts and scientists have been invited to share in the "source" of new drugs.
The clinical value is the goal, and the multi-line development strategy of "large and small molecules" will be explored.
There will be 1500+ industry elites in the field of innovative drugs to attend and participate, to create a research and development trend from drug discovery, preclinical to clinical development, CMC and technology, and the whole process of listing.
An exchange platform with innovative biomedicine with cutting-edge technologies!

Early bird last week, 3 get 1 free

Activity 1 Register

On the basis of the second

Welcome to consult the conference assistant: 18017939885 (same as WeChat)
or scan the corresponding QR code below to consult the discount details

Special thanks to the following partners for their support

BPC 2022 Sponsorship/Exhibitor Recruitment
Deadline
Only the last two booths are left in one week! Book now!
Consultation for details: Tel: 180 1793 9885 (same as WeChat)

The above rankings are in no particular order
.
More cooperative units will continue to update.

Scan the QR code above for more meeting details

For more conference details, please contact:
Mobile: 180 1793 9885 (same number on WeChat)
Email: marketing@bmapglobal.
com